Scholar Rock
Biotechnology Research • 
Cambridge, Massachusetts, United States • 201-500 Employees
Company overview
| Headquarters | 301 Binney St, Cambridge, Massachusetts 02142, US |
| Phone number | +18572593860 |
| Website | |
| SIC | 873 |
| Founded | 2012 |
| Employees | 201-500 |
| Socials |
Key Contacts at Scholar Rock
Matt Larson
Sr. Director, Talent Management
Richard Brudnick
Member Board Of Directors
Antrice Kay
National Account Director
Chuck Shannon
Senior Director, Gcp Quality Assurance
Elizabeth Pham
Senior Director, Head Of Medical Writing
Jen Gette
Sr Director, National Patient Access And Experience Lead
Erik Osterlund
Director G&A Applications
Denise Vosseller
Director Of Patient Marketing
Rita Watkins
Senior Director, Commercial Training
Susan Henry
Senior Director, Translational Sciences
Scholar Rock Email Formats
Scholar Rock uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@scholarrock.com), used 82.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@scholarrock.com | 82.2% |
{first initial}{last name} | jdoe@scholarrock.com | 16.2% |
{last name}{last name} | doedoe@scholarrock.com | 1.2% |
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock on X. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
Scholar Rock revenue & valuation
| Annual revenue | $33,200,000 |
| Revenue per employee | $101,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $106,300,000 |
| Total funding | $385,000,000 |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Scholar Rock has 141 employees across 16 departments.
Departments
Number of employees
Funding Data
Explore Scholar Rock's funding history, including investment rounds, total capital raised, and key backers.
Scholar Rock Tech Stack
Discover the technologies and tools that power Scholar Rock's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Security
JavaScript libraries
Page builders
JavaScript libraries
CDN
Font scripts
WordPress themes
JavaScript libraries
Miscellaneous
Programming languages
Blogs
Saudi Arabia
Morocco
United Kingdom
Australia
Frequently asked questions
4.8
40,000 users
